Reported Earlier: Biogen And Stoke Therapeutics Report Durable Seizure Reductions And Cognitive Improvements With Zorevunersen In Dravet Syndrome; Zorevunersen Generally Well Tolerated Across All Studies; Data Support Pivotal Phase 3 EMPORER Study Now Underway

Author: Benzinga Newsdesk | September 02, 2025 08:56am

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies –

– Substantial increase in seizure-free days and continuous improvements in quality of life demonstrated in patients already taking standard of care anti-seizure medicines –

– Zorevunersen generally well tolerated across all studies –

– Data support pivotal Phase 3 EMPEROR study now underway –

CAMBRIDGE, Mass. and BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epilepsy Congress (IEC) in Lisbon, Portugal. Data support the EMPEROR Phase 3 study of zorevunersen that is now underway to further evaluate this investigational antisense oligonucleotide.

Posted In: BIIB STOK